Werewolf Therapeutics (HOWL) Assets Average (2021 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Assets Average of $41.1 million for Q2 2026, down 58.87% year-over-year from $99.9 million in Q2 2025, and down 35.51% on a QoQ basis from $63.7 million in Q1 2026.
Werewolf Therapeutics (HOWL) Assets Average (2021 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Assets Average for 6 years, with the latest figure at $41.1 million in Q2 2026.
- Assets Average for Q2 2026 came in at $41.1 million, down 58.87% year-over-year; the trailing twelve-month figure through Jun 2026 was $41.1 million (down 58.87% YoY), and the FY2025 annual result was $98.2 million, down 34.94% from the prior year.
- Assets Average slipped to $41.1 million in Q2 2026, from $63.7 million in the prior quarter.
- Over five years, Assets Average peaked at $190.2 million in Q2 2023 and troughed at $41.1 million in Q2 2026.
- A 5-year average of $139.5 million and a median of $166.0 million in 2022 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average soared 85.05%; it then sank 58.87% in 2026.
- A 5-year view of Assets Average shows it stood at $166.3 million in 2022, then climbed by 5.58% to $175.6 million in 2023, then declined by 23.99% to $133.5 million in 2024, then slumped by 44.18% to $74.5 million in 2025, then sank by 44.86% to $41.1 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $41.1 million in Q2 2026, $63.7 million in Q1 2026, and $74.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Werewolf Therapeutics | 20.90 Mn | 20.90 Mn | - | 41.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.09 Mn |
| Mar 31, 2026 | 63.71 Mn |
| Dec 31, 2025 | 74.51 Mn |
| Sep 30, 2025 | 86.10 Mn |
| Jun 30, 2025 | 99.90 Mn |
| Mar 31, 2025 | 117.08 Mn |
| Dec 31, 2024 | 133.48 Mn |
| Sep 30, 2024 | 146.87 Mn |
| Jun 30, 2024 | 165.65 Mn |
| Mar 31, 2024 | 176.22 Mn |
| Dec 31, 2023 | 175.61 Mn |
| Sep 30, 2023 | 180.81 Mn |
| Jun 30, 2023 | 190.15 Mn |
| Mar 31, 2023 | 177.66 Mn |
| Dec 31, 2022 | 166.33 Mn |
| Sep 30, 2022 | 173.88 Mn |
| Jun 30, 2022 | 169.98 Mn |
| Mar 31, 2022 | 171.94 Mn |
| Dec 31, 2021 | 178.81 Mn |
| Sep 30, 2021 | 184.40 Mn |